Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision to make Global Bioprocessing Simpler and more Efficient. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, as well as other industries involving bioprocessing (e.g. Synthetic Biology, IVD, CGT, etc.). Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States. GBB has launched multiple proprietary AI biotech platforms; AlfaCell®, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX® platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 26 patents, with 12 related to AI and 14 related to biology, to protect these innovations. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies. As of the end of 2022, GBB has completed three financing rounds, raising over US $30 million.
